Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polyspecific Sri Lankan antivenom
- Development stage
- Preclinical
- Lead developer
- Instituto Clodomiro Picado
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Polyspecific Sri Lankan antivenom is a lyophilized hyperimmune serum containing polyclonal antibodies developed by the Instituto Clodomiro Picado (ICP). It is specifically designed to neutralize the toxins from the four most medically significant venomous snakes found in Sri Lanka: *Daboia russelli* (Russell's viper), *Hypnale hypnale* (Hump-nosed pit viper), *Echis carinatus* (Saw-scaled viper), and *Naja naja* (Indian cobra). The antivenom works by binding to and neutralizing various venom components, including phospholipases A2, metalloproteinases, and neurotoxins, thereby preventing or reversing the systemic and local effects of envenomation. The product is currently in the preclinical development phase and is intended for human use in treating snakebite envenomation in the Sri Lankan region.
- Other names
- polyspecific Sri Lankan antivenomlyophilized polyclonal antivenom for Daboia russelli, Hypnale hypnale, Echis carinatus, Naja najaICP Sri Lankan antivenom
02
Targets
Hypnale hypnale venom toxinsRVV-X (Russell's viper venom factor X activator)PLA2 (Phospholipase A2 group IID)
Beyond the preview
Go deeper on polyspecific Sri Lankan antivenom.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polyspecific Sri Lankan antivenom.